TG Therapeutics, Inc. (TGTX) P/E Ratio History
UndervaluedTrading at 19.2x vs 5Y avg 178.2x · 54th percentile · Below historical baseline · Data 2011–2026
Loading P/E history...
P/E Ratio Analysis
As of June 21, 2026, TG Therapeutics, Inc. (TGTX) trades at a price-to-earnings ratio of 19.2x, with a stock price of $53.22 and trailing twelve-month earnings per share of $2.89.
The current P/E is 89% below its 5-year average of 178.2x. Over the past five years, TGTX's P/E has ranged from a low of 0.0x to a high of 1708.0x, placing the current valuation at the 54th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, TGTX is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, TGTX trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TGTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TGTX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
TGTX P/E vs Peers
Immunology and Inflammation Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $115B | 29.5 | 3.56 | +837% | |
| $7B | 31.5 | - | -34% | |
| $29B | 22.3 | - | -21% | |
| $154B | 18.3 | 0.14Best | +1684% | |
| $383B | 91.4 | - | -1% | |
| $20B | 15.3Lowest | - | +4173%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
TGTX Historical P/E Data (2011–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $33.22 | $2.86 | 11.6x | -93% |
| FY2025 Q4 | Dec 31 2025 | $29.81 | $2.77 | 10.8x | -94% |
| FY2025 Q3 | - | $36.13 | $2.78 | 13.0x | -93% |
| FY2025 Q2 | Jun 30 2025 | $35.99 | $0.37 | 97.0x | -46% |
| FY2025 Q1 | Mar 31 2025 | $39.43 | $0.24 | 161.4x | -9% |
| FY2024 Q4 | - | $30.10 | $0.14 | 215.0x | +21% |
| FY2024 Q2 | Jun 30 2024 | $17.79 | $0.60 | 29.6x | -83% |
| FY2024 Q1 | Mar 31 2024 | $15.21 | $0.22 | 70.2x | -61% |
| FY2023 Q4 | Dec 31 2023 | $17.08 | $0.01 | 1708.0x | +858% |
| FY2011 Q4 | Dec 31 2011 | $1.13 | $80.96 | 0.0x | -100% |
| FY2011 Q3 | Sep 30 2011 | $6.19 | $81.22 | 0.1x | -100% |
| FY2011 Q2 | - | $16.88 | $82.55 | 0.2x | -100% |
| FY2011 Q1 | - | $39.38 | $127.50 | 0.3x | -100% |
Average P/E for displayed period: 178.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
15+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TGTX — Frequently Asked Questions
Quick answers to the most common questions about buying TGTX stock.
What is TGTX's P/E ratio?
TG Therapeutics, Inc. (TGTX) trailing twelve-month P/E ratio is 19.2x, based on TTM diluted EPS of $2.89. The 5-year average P/E is 178.2x and the historical range spans 0.0x to 1708.0x.
Is TGTX stock overvalued or undervalued?
TGTX trades at 19.2x P/E, below its 5-year average of 178.2x. At the 54th percentile of its historical range (0.0x–1708.0x), the stock is priced at a discount to its own history.
Is TGTX stock expensive?
No, TGTX is not expensive on a historical basis. The current P/E of 19.2x is below the 5-year average of 178.2x and sits at the 54th percentile of its valuation range.
What is TGTX's historical P/E range?
Over the past 5 years, TGTX's P/E ratio has ranged from 0.0x to 1708.0x, with a median of 13.0x and an average of 178.2x. The current P/E of 19.2x places the stock at the 54th percentile of this range. Full historical data spans 2011–2026.
How does TGTX's P/E compare to the S&P 500?
TGTX trades at 19.2x P/E versus the S&P 500 median of 24.4x. The 21% discount to the market suggests lower growth expectations or perceived higher risk.
How does TGTX's valuation compare to Healthcare peers?
TG Therapeutics, Inc. P/E of 19.2x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is TGTX's PEG ratio?
TGTX PEG ratio is N/A, based on a P/E of 19.2x and EPS growth of 1746.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is TGTX's earnings yield?
TGTX earnings yield is 5.20%, the inverse of its 19.2x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.